Literature DB >> 11071849

Overexpression of DAN causes a growth suppression in p53-deficient SAOS-2 cells.

E Hanaoka1, T Ozaki, Y Nakamura, H Moriya, A Nakagawara, S Sakiyama.   

Abstract

It has been shown that the expression of DAN as well as Drm/Gremlin, a member of DAN/Cerberus family, is significantly down-regulated in rodent fibroblasts transformed with various oncogenes and overexpression of DAN results in the phenotypic reversion of the transformed phenotypes. In the present study, we examined the expression levels of DAN, BMP-2, BMP-4, and BMPRs (BMP receptors) in five human cell lines derived from bone and soft tissue tumors. Northern blot analysis revealed that DAN mRNA was detected in OS-KH and RMS-NK cells, but was not detectable in SAOS-2, NOS-1, and ASPS-KY cells. Transient overexpression of DAN in SAOS-2 cells, which lack functional p53 and pRB, resulted in a remarkable growth suppression without the induction of p21(Waf1). Interestingly, overexpression of DAN was associated with a reduction of alkaline phosphatase activity in SAOS-2 cells. Stable transfection of DAN in SAOS-2 cells caused a significant reduction of numbers of drug-resistant colonies, whereas the truncated form of DAN which lacked a possible signal peptide, completely lost this capability. Our results suggest that the secreted form of DAN exerts its growth-suppressive function in SAOS-2 cells in a p53-independent manner. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11071849     DOI: 10.1006/bbrc.2000.3758

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.

Authors:  David G Winkler; May Kung Sutherland; James C Geoghegan; Changpu Yu; Trenton Hayes; John E Skonier; Diana Shpektor; Mechtild Jonas; Brian R Kovacevich; Karen Staehling-Hampton; Mark Appleby; Mary E Brunkow; John A Latham
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

2.  Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro.

Authors:  Wei Zhu; Jaehon Kim; Christina Cheng; Bernard A Rawlins; Oheneba Boachie-Adjei; Ronald G Crystal; Chisa Hidaka
Journal:  Bone       Date:  2006-02-20       Impact factor: 4.398

3.  GnRH-mediated DAN production regulates the transcription of the GnRH receptor in gonadotrope cells.

Authors:  Rakel López de Maturana; Bronwen Martin; Robert P Millar; Pamela Brown; Lindsay Davidson; Adam J Pawson; Moira R Nicol; J Ian Mason; Perdita Barran; Zvi Naor; Stuart Maudsley
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

4.  The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein.

Authors:  Hong Namkoong; Seung Min Shin; Hyun Kee Kim; Seon-Ah Ha; Goang Won Cho; Soo Young Hur; Tae Eung Kim; Jin Woo Kim
Journal:  BMC Cancer       Date:  2006-03-18       Impact factor: 4.430

5.  Inhibitory effect of NBL1 on PDGF-BB-induced human PASMC proliferation through blockade of PDGFβ-p38MAPK pathway.

Authors:  Chuanjue Cui; Hongliang Zhang; Lin-Na Guo; Xiaoling Zhang; Liukun Meng; Xiangbin Pan; Yingjie Wei
Journal:  Biosci Rep       Date:  2016-08-31       Impact factor: 3.840

6.  DAN (NBL1) promotes collective neural crest migration by restraining uncontrolled invasion.

Authors:  Rebecca McLennan; Caleb M Bailey; Linus J Schumacher; Jessica M Teddy; Jason A Morrison; Jennifer C Kasemeier-Kulesa; Lauren A Wolfe; Madeline M Gogol; Ruth E Baker; Philip K Maini; Paul M Kulesa
Journal:  J Cell Biol       Date:  2017-08-15       Impact factor: 10.539

7.  DNA alteration-based classification of uveal melanoma gives better prognostic stratification than immune infiltration, which has a neutral effect in high-risk group.

Authors:  Deepti Narasimhaiah; Catherine Legrand; Diane Damotte; Romain Remark; Marco Munda; Patrick De Potter; Pierre G Coulie; Miikka Vikkula; Catherine Godfraind
Journal:  Cancer Med       Date:  2019-04-25       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.